The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II/III study of sotatercept (ACE-011), an activin antagonist, for chemotherapy-induced anemia in patients with metastatic non-small cell lung cancer treated with first-line platinum-based chemotherapy.
H. Raftopoulos
No relevant relationships to disclose
A. Laadem
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
M. Puccio
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
R. D. Knight
Employment or Leadership Position - Celgene
Stock Ownership - Celgene